China
0
Room 217, Building 2
Add Favorite
Report Supplier
Business Description
Tigsun Diagnostics Co., Ltd is a high-tech enterprise which specializes in R&D, manufacture and sales of IVD products and possesses well-developed platform for IVD reagents and support analyzers. Tigsun mainly produce ELISA and CLIA diagnostic kits, including reproductive hormones, thyroid function, hepatitis B series, liver fibrosis series, diabetes disease, tumor markers, infertility, TORCH, prenatal screening, virus series, renal function, anemia series, etc., about 90 kinds of IVD reagents. Reagent facility has been GMP certified by SFDA in China. Tigsun has passed ISO9001:2000 and ISO 13485:2003 certification. Tigsun manufacture high-quality CLIA analyzer, including MP180 CLIA analyzer, MP280 CLIA analyzer, prenatal screening instrument and MP480 CLIA analyzer. CLIA analyzer works together with user-friendly software, realizing multifunction operations. Tigsun also produce support instruments for CLIA and ELISA tests, for example, thermostatic oscillator, which has incubation, shaking and timing functions with capacity of 6 plates and 12 plates. Tigsun dedicates itself to provide high-quality products and after-sale service. So far, Tigsun????? products have been used by thousands of hospitals in China and exported to Southeast Asia and India. Tigsun will exert all efforts to meet customers?????needs
Export Capabilities
Declared by supplierTigsun Diagnostics Co.,Ltd. has been exporting since 2004.
Export start year
2004
Trade Capabilities
Business Terms
Trade Ability
Diagnostic Kits market insight
As of 14 November 2026, 9 suppliers in 6 countries offer 9 active supply listings on Freshdi across Medical & HealthCare, the group Diagnostic Kits belongs to. Suppliers across Medical & HealthCare, the wider group Diagnostic Kits belongs to, come from 6 countries, led by India at 22.2%, on Freshdi as of 14 November 2026. Buyer inquiry volume across Medical & HealthCare, the wider group Diagnostic Kits belongs to, rose 100% on Freshdi in the 30 days to 14 November 2026 against the 30 days before, with 103.41% volatility in monthly inquiry and quotation activity over 338 days.
